普罗布考与辛伐他汀联合治疗对急性冠状动脉综合征患者血氧化低密度脂蛋白和高敏C反应蛋白水平的影响

目的评价普罗布考与辛伐他汀联合治疗对急性冠状动脉综合征患者血氧化低密度脂蛋白和高教c反应蛋白水平的影响。方法120例急性冠脉综合征的患者随机分为单药治疗组（n=60,辛伐他汀20mg／d）和联合治疗组（n=60,辛伐他汀20mg／d＋普罗布考500mg／d）。于入院或就诊24小时内和治疗后4周、8周时检测血总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白（HDL—C）、低密度脂蛋白（LDL—C）、高敏C反应蛋白（hs—CRP）及氧化低密度脂蛋白（ox—LDL）,统计两组不良反应发生情况,并比较差异。结果治疗8周后联合治疗组的血低密度脂蛋白胆固醇、氧化低密度脂蛋白、高敏c反应蛋白较单药治疗组下降更明显,差异有统计学意义（P〈0．01）,相关分析提示氧化低密度脂蛋白与高敏c反应蛋白之间具有相关性（r=0．55,P〈0．01）。结论抗氧化剂普罗布考与辛伐他汀联合应用能更进一步降低急性冠脉综合征患者的血脂、OX—LDL及炎症因子的水平。可能通过上述机制起到稳定斑块的作用,为急性冠脉综合征的药物治疗颁域增加了新证据。

Effect of Probucol and Simvastatin Combined Medication on the levels of Oxidized Low Density Lipoprotein and High Sensitivity C-reactive Protein in Patients With Acute Coronary Syndrome

Objective To evaluate the effect of probucol and simvastatin combined medication on the levels of ox idized low density lipoprotein（ OX- LDL） and high sensitivity C- reactive protein in Patients With Acute Coronary Syndrome. Methods A tota 1 of 120 patieots with acute coronary syndrome were randomly divided into two groups： Single medicationg roup（n = 60）, the patients were taken simvzstatiu 20mg/d; and combined medication group（n = 60）, the patients were taken simvastatin 20mg/d and probucol 500mg/d. within 24 hous of medication, high sensitivity C - reactive protein（ hs CRP）, OX- LDL, and blood lipids were mesured, the above items were reexanuned after the medication 4 weeks and 8 weeks respectively. Results Compared with single medication group, 8 weeks after the medication , love lipoprotein cholesterol（ LDL- C）, OX - LDL and hs - CRP were significantly decreased in combined medication group（P 〈 0.01）, there was a relationship between OX- LDL and hsCRP（r = 0.55, P 〈 0.01 ）. Conclusion Probueol and simvastatin combined medication could signifieantly decrease the blood levels of OX - LDL, LDL- C and hs - CRP. It indicated that decreased level of blood lipids and antiinflammation, antioxidation might stabilize the plaques in ACS patients and therefore reduce the risk of ACS.